Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2009 1
2010 1
2011 1
2013 4
2014 3
2015 1
2016 1
2017 4
2018 1
2019 1
2020 1
2021 1
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A; INOVATYON study group. Colombo N, et al. Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9. Br J Cancer. 2023. PMID: 36759720 Free PMC article. Clinical Trial.
Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer.
Fasching PA, Liu D, Scully S, Ingle JN, Lyra PC, Rack B, Hein A, Ekici AB, Reis A, Schneeweiss A, Tesch H, Fehm TN, Heinrich G, Beckmann MW, Ruebner M, Huebner H, Lambrechts D, Madden E, Shen J, Romm J, Doheny K, Jenkins GD, Carlson EE, Li L, Fridley BL, Cunningham JM, Janni W, Monteiro ANA, Schaid DJ, Häberle L, Weinshilboum RM, Wang L. Fasching PA, et al. Among authors: heinrich g. Clin Cancer Res. 2022 Aug 2;28(15):3342-3355. doi: 10.1158/1078-0432.CCR-20-4774. Clin Cancer Res. 2022. PMID: 35653140 Free PMC article.
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients.
Huebner H, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S, Jückstock J, Nabieva N, Schneeweiss A, Tesch H, Brucker SY, Blohmer JU, Fehm TN, Heinrich G, Rezai M, Beckmann MW, Fasching PA, Janni W, Rack B. Huebner H, et al. Among authors: heinrich g. Cancers (Basel). 2022 Mar 28;14(7):1721. doi: 10.3390/cancers14071721. Cancers (Basel). 2022. PMID: 35406491 Free PMC article.
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
de Gregorio A, Häberle L, Fasching PA, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl TWP, Bauer E, de Gregorio N, Deniz M, Fink V, Bekes I, Andergassen U, Schneeweiss A, Tesch H, Mahner S, Brucker SY, Blohmer JU, Fehm TN, Heinrich G, Lato K, Beckmann MW, Rack B, Janni W. de Gregorio A, et al. Among authors: heinrich g. Breast Cancer Res. 2020 Oct 23;22(1):111. doi: 10.1186/s13058-020-01348-w. Breast Cancer Res. 2020. PMID: 33097092 Free PMC article. Clinical Trial.
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial.
Friedl TWP, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J, Jückstock J, Schneeweiss A, Tesch H, Mahner S, Brucker SY, Heinrich G, Häberle L, Fasching PA, Beckmann MW, Coleman RE, Janni W, Rack B. Friedl TWP, et al. Among authors: heinrich g. JAMA Oncol. 2021 Aug 1;7(8):1149-1157. doi: 10.1001/jamaoncol.2021.1854. JAMA Oncol. 2021. PMID: 34165508 Free PMC article. Clinical Trial.
Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial.
Trapp EK, Fasching PA, Fehm T, Schneeweiss A, Mueller V, Harbeck N, Lorenz R, Schumacher C, Heinrich G, Schochter F, de Gregorio A, Tzschaschel M, Rack B, Janni W, Friedl TWP. Trapp EK, et al. Among authors: heinrich g. Cancers (Basel). 2022 Aug 16;14(16):3949. doi: 10.3390/cancers14163949. Cancers (Basel). 2022. PMID: 36010945 Free PMC article.
The Endocrine Treatment Landscape for Patients with HR+ HER2- Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy - A Real-World Analysis.
Nabieva N, Altmann F, Apel K, Baerens DT, Beha M, Belau A, Busch S, Guth D, Heinrich G, Kreiss-Sender J, Markmann S, Olbermann A, Oskay-Özcelik G, Schuback B, Steinfeld-Birg D, Quiering C, Kiss F, Kreuzeder J, Nuti P, Schilling J. Nabieva N, et al. Among authors: heinrich g. Geburtshilfe Frauenheilkd. 2023 Jul 18;83(9):1127-1137. doi: 10.1055/a-2100-0643. eCollection 2023 Sep. Geburtshilfe Frauenheilkd. 2023. PMID: 37942358 Free PMC article.
Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity.
Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L. Fasching PA, et al. Among authors: heinrich g. Oncotarget. 2017 May 9;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100455 Free PMC article.
22 results